(VIANEWS) – The NASDAQ opens in less than one hour and Amicus Therapeutics‘s pre-market value is already 4.44% down.
Amicus Therapeutics’s last close was $11.72, 19.56% under its 52-week high of $14.57.
The last session, NASDAQ ended with Amicus Therapeutics (FOLD) rising 2.27% to $11.72. NASDAQ jumped 1.24% to $16,248.52, following the last session’s upward trend on what was an all-around bullish trend trading session.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Earnings Per Share
As for profitability, Amicus Therapeutics has a trailing twelve months EPS of $-0.51.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.04%.
Yearly Top and Bottom Value
Amicus Therapeutics’s stock is valued at $11.72 at 09:23 EST, way under its 52-week high of $14.57 and way higher than its 52-week low of $9.70.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 66.7% and 86.7%, respectively.
More news about Amicus Therapeutics (FOLD).
